(PGNY) Progyny - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US74340E1038
Fertility Benefits, Pharmacy Solution, Adoption Assistance
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 47.0% |
| Value at Risk 5%th | 70.2% |
| Relative Tail Risk | -9.19% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.27 |
| Alpha | 60.11 |
| CAGR/Max DD | -0.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.449 |
| Beta | 0.524 |
| Beta Downside | 0.249 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.14% |
| Mean DD | 32.18% |
| Median DD | 34.99% |
Description: PGNY Progyny November 11, 2025
Progyny, Inc. (NASDAQ:PGNY) is a U.S. benefits-management firm that specializes in fertility, family-building, and women’s health solutions for employers. Its product suite includes a differentiated fertility benefits design (e.g., smart-cycle treatment bundles), concierge-style member support, a curated network of fertility specialists, an integrated pharmacy offering (Progyny Rx) with medication access and care-management, and a reimbursement-based assistance program covering adoption, surrogacy, doula services, and travel costs.
Key operational metrics (FY 2023) show revenue of approximately $1.5 billion, up roughly 30% year-over-year, driven by a 45% increase in covered lives to about 8 million members. The fertility-benefits market is expanding at a 12% CAGR, fueled by rising infertility rates (≈15% of U.S. couples) and growing employer demand for comprehensive family-building perks. A sector-wide driver is the shift toward value-based care, which aligns with Progyny’s bundled-payment model and its emphasis on outcome-based care coordination.
For a deeper, data-rich assessment of Progyny’s valuation dynamics, you may find ValueRay’s analytical platform useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (56.6m TTM) > 0 and > 6% of Revenue (6% = 76.1m TTM) |
| FCFTA 0.24 (>2.0%) and ΔFCFTA -0.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.44% (prev 29.67%; Δ 2.77pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.26 (>3.0%) and CFO 205.1m > Net Income 56.6m (YES >=105%, WARN >=100%) |
| Net Debt (-109.3m) to EBITDA (95.4m) ratio: -1.14 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (90.2m) change vs 12m ago -3.83% (target <= -2.0% for YES) |
| Gross Margin 22.94% (prev 21.68%; Δ 1.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 174.4% (prev 172.5%; Δ 1.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -21.47 (EBITDA TTM 95.4m / Interest Expense TTM -4.24m) >= 6 (WARN >= 3) |
Altman Z'' 5.87
| (A) 0.52 = (Total Current Assets 622.0m - Total Current Liabilities 210.5m) / Total Assets 795.2m |
| (B) 0.24 = Retained Earnings (Balance) 190.3m / Total Assets 795.2m |
| (C) 0.13 = EBIT TTM 91.0m / Avg Total Assets 727.6m |
| (D) 0.81 = Book Value of Equity 190.8m / Total Liabilities 235.2m |
| Total Rating: 5.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.44
| 1. Piotroski 5.50pt |
| 2. FCF Yield 10.51% |
| 3. FCF Margin 15.01% |
| 4. Debt/Equity 0.04 |
| 5. Debt/Ebitda -1.14 |
| 6. ROIC - WACC (= 2.84)% |
| 7. RoE 11.52% |
| 8. Rev. Trend 88.59% |
| 9. EPS Trend 80.71% |
What is the price of PGNY shares?
As of December 14, 2025, the stock is trading at USD 26.71 with a total of 1,582,229 shares traded.
Over the past week, the price has changed by +11.20%, over one month by +10.97%, over three months by +18.66% and over the past year by +79.74%.
Over the past week, the price has changed by +11.20%, over one month by +10.97%, over three months by +18.66% and over the past year by +79.74%.
Is PGNY a buy, sell or hold?
Progyny has received a consensus analysts rating of 3.80.
Therefor, it is recommend to hold PGNY.
- Strong Buy: 4
- Buy: 0
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PGNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.1 | 8.9% |
| Analysts Target Price | 29.1 | 8.9% |
| ValueRay Target Price | 29.3 | 9.8% |
PGNY Fundamental Data Overview December 11, 2025
Market Cap USD = 2.13b (2.13b USD * 1.0 USD.USD)
P/E Trailing = 39.871
P/E Forward = 12.3001
P/S = 1.6798
P/B = 3.8056
Beta = 0.972
Revenue TTM = 1.27b USD
EBIT TTM = 91.0m USD
EBITDA TTM = 95.4m USD
Long Term Debt = 24.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.86m USD (from shortTermDebt, last fiscal year)
Debt = 24.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -109.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.81b USD (2.13b + Debt 24.7m - CCE 345.2m)
Interest Coverage Ratio = -21.47 (Ebit TTM 91.0m / Interest Expense TTM -4.24m)
FCF Yield = 10.51% (FCF TTM 190.4m / Enterprise Value 1.81b)
FCF Margin = 15.01% (FCF TTM 190.4m / Revenue TTM 1.27b)
Net Margin = 4.46% (Net Income TTM 56.6m / Revenue TTM 1.27b)
Gross Margin = 22.94% ((Revenue TTM 1.27b - Cost of Revenue TTM 977.7m) / Revenue TTM)
Gross Margin QoQ = 23.24% (prev 23.72%)
Tobins Q-Ratio = 2.28 (Enterprise Value 1.81b / Total Assets 795.2m)
Interest Expense / Debt = 2.85% (Interest Expense 706.0k / Debt 24.7m)
Taxrate = 42.15% (10.1m / 24.0m)
NOPAT = 52.6m (EBIT 91.0m * (1 - 42.15%))
Current Ratio = 2.96 (Total Current Assets 622.0m / Total Current Liabilities 210.5m)
Debt / Equity = 0.04 (Debt 24.7m / totalStockholderEquity, last quarter 560.0m)
Debt / EBITDA = -1.14 (Net Debt -109.3m / EBITDA 95.4m)
Debt / FCF = -0.57 (Net Debt -109.3m / FCF TTM 190.4m)
Total Stockholder Equity = 491.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.11% (Net Income 56.6m / Total Assets 795.2m)
RoE = 11.52% (Net Income TTM 56.6m / Total Stockholder Equity 491.1m)
RoCE = 17.64% (EBIT 91.0m / Capital Employed (Equity 491.1m + L.T.Debt 24.7m))
RoIC = 10.72% (NOPAT 52.6m / Invested Capital 491.1m)
WACC = 7.88% (E(2.13b)/V(2.16b) * Re(7.95%) + D(24.7m)/V(2.16b) * Rd(2.85%) * (1-Tc(0.42)))
Discount Rate = 7.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -5.37%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈178.4m ; Y1≈220.1m ; Y5≈375.5m
Fair Price DCF = 74.07 (DCF Value 6.39b / Shares Outstanding 86.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 80.71 | EPS CAGR: 34.04% | SUE: 2.62 | # QB: 2
Revenue Correlation: 88.59 | Revenue CAGR: 27.08% | SUE: 1.14 | # QB: 4
EPS next Quarter (2026-03-31): EPS=0.49 | Chg30d=+0.001 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=1.94 | Chg30d=+0.056 | Revisions Net=+5 | Growth EPS=+7.6% | Growth Revenue=+9.5%
P/E Trailing = 39.871
P/E Forward = 12.3001
P/S = 1.6798
P/B = 3.8056
Beta = 0.972
Revenue TTM = 1.27b USD
EBIT TTM = 91.0m USD
EBITDA TTM = 95.4m USD
Long Term Debt = 24.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.86m USD (from shortTermDebt, last fiscal year)
Debt = 24.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -109.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.81b USD (2.13b + Debt 24.7m - CCE 345.2m)
Interest Coverage Ratio = -21.47 (Ebit TTM 91.0m / Interest Expense TTM -4.24m)
FCF Yield = 10.51% (FCF TTM 190.4m / Enterprise Value 1.81b)
FCF Margin = 15.01% (FCF TTM 190.4m / Revenue TTM 1.27b)
Net Margin = 4.46% (Net Income TTM 56.6m / Revenue TTM 1.27b)
Gross Margin = 22.94% ((Revenue TTM 1.27b - Cost of Revenue TTM 977.7m) / Revenue TTM)
Gross Margin QoQ = 23.24% (prev 23.72%)
Tobins Q-Ratio = 2.28 (Enterprise Value 1.81b / Total Assets 795.2m)
Interest Expense / Debt = 2.85% (Interest Expense 706.0k / Debt 24.7m)
Taxrate = 42.15% (10.1m / 24.0m)
NOPAT = 52.6m (EBIT 91.0m * (1 - 42.15%))
Current Ratio = 2.96 (Total Current Assets 622.0m / Total Current Liabilities 210.5m)
Debt / Equity = 0.04 (Debt 24.7m / totalStockholderEquity, last quarter 560.0m)
Debt / EBITDA = -1.14 (Net Debt -109.3m / EBITDA 95.4m)
Debt / FCF = -0.57 (Net Debt -109.3m / FCF TTM 190.4m)
Total Stockholder Equity = 491.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.11% (Net Income 56.6m / Total Assets 795.2m)
RoE = 11.52% (Net Income TTM 56.6m / Total Stockholder Equity 491.1m)
RoCE = 17.64% (EBIT 91.0m / Capital Employed (Equity 491.1m + L.T.Debt 24.7m))
RoIC = 10.72% (NOPAT 52.6m / Invested Capital 491.1m)
WACC = 7.88% (E(2.13b)/V(2.16b) * Re(7.95%) + D(24.7m)/V(2.16b) * Rd(2.85%) * (1-Tc(0.42)))
Discount Rate = 7.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -5.37%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈178.4m ; Y1≈220.1m ; Y5≈375.5m
Fair Price DCF = 74.07 (DCF Value 6.39b / Shares Outstanding 86.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 80.71 | EPS CAGR: 34.04% | SUE: 2.62 | # QB: 2
Revenue Correlation: 88.59 | Revenue CAGR: 27.08% | SUE: 1.14 | # QB: 4
EPS next Quarter (2026-03-31): EPS=0.49 | Chg30d=+0.001 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=1.94 | Chg30d=+0.056 | Revisions Net=+5 | Growth EPS=+7.6% | Growth Revenue=+9.5%
Additional Sources for PGNY Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle